Can AI identify early-stage lung cancer from breath biomarkers using portable electronic noses ?

Could breath biomarkers be the key to detecting lung cancer early, using nothing more complex than a portable electronic nose? The idea hinges on detecting subtle chemical changes in exhaled air that precede visible tumors, offering a potential alternative to invasive biopsies or CT scans. Yet real-world feasibility remains tangled in environmental noise and technical hurdles.

Background

Researchers have demonstrated that portable electronic noses (e-noses) can detect volatile organic compounds (VOCs) in exhaled breath with promising sensitivity and specificity for early-stage lung cancer screening. A 2022 meta-analysis reported pooled sensitivity of about 85% and specificity of 87% across multiple studies using machine-learning models trained on breath-chemistry data. Certain volatile organic compounds in exhaled breath change in presence of early lung cancer, even before imaging detects tumors, and AI-powered e-noses could analyze breath samples in clinics or pharmacies, reducing reliance on invasive diagnostics. However, environmental factors like smoking or air pollution may confound results. Furthermore, real-world deployment faces challenges such as sensor drift, environmental confounders like smoking or diet, and the need for larger, multi-center validation cohorts. Regulatory approval remains limited to a few devices with narrow indications, underscoring the gap between promising research and routine clinical use.